ICON PLC's ticker is ICLR and the CUSIP is G4705A100. A total of 502 filers reported holding ICON PLC in Q2 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
About ICON PLC
ICON PLC: A Leading Provider of Clinical Research Services
ICON PLC is a global provider of clinical research services to the pharmaceutical, biotechnology, and medical device industries. The company was founded in 1990 and is headquartered in Dublin, Ireland. With over 14,000 employees in 97 locations across 40 countries, ICON is one of the largest clinical research organizations in the world.
ICON offers a wide range of services to its clients, including clinical trial management, data management, biostatistics, medical imaging, and regulatory consulting. The company's expertise in these areas allows it to help its clients bring new drugs and medical devices to market faster and more efficiently.
One of ICON's key strengths is its focus on innovation. The company invests heavily in technology and has developed a number of proprietary tools and platforms to help streamline the clinical trial process. For example, ICON's Firecrest platform provides online training and certification for clinical trial investigators, while its ICONIK platform allows clients to access real-time data on their clinical trials.
ICON has also been recognized for its commitment to quality and compliance. The company has received numerous awards for its work in these areas, including the Frost & Sullivan 2020 Global CRO Customer Value Leadership Award.
Overall, ICON PLC is a leading provider of clinical research services with a strong track record of innovation, quality, and compliance. With the demand for clinical research services expected to continue growing in the coming years, ICON is well-positioned to capitalize on this trend and deliver value to its clients and shareholders alike.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $801,544 | -7.6% | 3,255 | -6.1% | 0.00% | -50.0% |
Q2 2023 | $867,443 | -66.0% | 3,467 | -70.6% | 0.00% | 0.0% |
Q2 2022 | $2,554,000 | -89.9% | 11,787 | -85.5% | 0.00% | -88.2% |
Q4 2021 | $25,168,000 | -26.7% | 81,270 | -38.0% | 0.02% | -37.0% |
Q3 2021 | $34,338,000 | +896.2% | 131,052 | +685.9% | 0.03% | +800.0% |
Q2 2021 | $3,447,000 | +730.6% | 16,675 | +447.1% | 0.00% | +200.0% |
Q1 2020 | $415,000 | -61.9% | 3,048 | -51.7% | 0.00% | 0.0% |
Q4 2019 | $1,088,000 | -90.9% | 6,315 | -92.2% | 0.00% | -91.7% |
Q3 2019 | $11,896,000 | -3.1% | 80,735 | +1.3% | 0.01% | +9.1% |
Q2 2019 | $12,274,000 | +8.9% | 79,719 | -3.4% | 0.01% | 0.0% |
Q1 2019 | $11,268,000 | +14.7% | 82,504 | +8.5% | 0.01% | 0.0% |
Q4 2018 | $9,822,000 | -17.3% | 76,013 | -1.5% | 0.01% | 0.0% |
Q3 2018 | $11,870,000 | +11.8% | 77,207 | -3.7% | 0.01% | +10.0% |
Q2 2018 | $10,620,000 | +21.0% | 80,132 | +7.9% | 0.01% | +25.0% |
Q1 2018 | $8,776,000 | +102.6% | 74,285 | +92.3% | 0.01% | +166.7% |
Q4 2017 | $4,332,000 | -39.4% | 38,629 | -56.9% | 0.00% | -57.1% |
Q1 2017 | $7,149,000 | -12.0% | 89,674 | -17.0% | 0.01% | 0.0% |
Q4 2016 | $8,121,000 | +4.7% | 107,989 | +6.3% | 0.01% | -12.5% |
Q3 2016 | $7,754,000 | +9.0% | 101,604 | +0.0% | 0.01% | 0.0% |
Q2 2016 | $7,111,000 | -71.6% | 101,578 | -69.5% | 0.01% | -72.4% |
Q1 2016 | $25,009,000 | +1.5% | 333,009 | +5.2% | 0.03% | +3.6% |
Q4 2015 | $24,641,000 | -0.9% | 316,642 | -9.6% | 0.03% | -6.7% |
Q3 2015 | $24,871,000 | +6.6% | 350,448 | +1.4% | 0.03% | +20.0% |
Q2 2015 | $23,332,000 | -29.3% | 345,728 | -26.1% | 0.02% | -34.2% |
Q1 2015 | $32,993,000 | +41.7% | 467,784 | +2.5% | 0.04% | +46.2% |
Q4 2014 | $23,279,000 | -29.8% | 456,531 | -21.4% | 0.03% | -35.0% |
Q3 2014 | $33,182,000 | +119.3% | 580,731 | +80.8% | 0.04% | +110.5% |
Q2 2014 | $15,130,000 | -4.6% | 321,169 | -3.7% | 0.02% | 0.0% |
Q1 2014 | $15,853,000 | +44.3% | 333,395 | +22.7% | 0.02% | +35.7% |
Q4 2013 | $10,985,000 | +27.8% | 271,812 | +29.5% | 0.01% | +27.3% |
Q3 2013 | $8,594,000 | +30.7% | 209,970 | +13.1% | 0.01% | +22.2% |
Q2 2013 | $6,575,000 | – | 185,590 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Trinity Street Asset Management LLP | 632,255 | $155,692,793 | 20.00% |
Eagle Health Investments LP | 186,200 | $45,851,750 | 10.10% |
FACT Capital, LP | 93,654 | $23,062,298 | 9.16% |
WILSON ASSET MANAGEMENT (INTERNATIONAL) PTY LTD | 99,260 | $24,525,161 | 7.04% |
COMGEST GLOBAL INVESTORS S.A.S. | 1,542,247 | $379,778,324 | 6.50% |
Montanaro Asset Management Ltd | 148,300 | $36,518,875 | 6.42% |
Kiwi Wealth Investments Limited Partnership | 223,753 | $55,099,176 | 6.00% |
WCM INVESTMENT MANAGEMENT, LLC | 7,594,972 | $1,870,261,855 | 5.49% |
AMERICAN CAPITAL MANAGEMENT INC | 523,980 | $129,030,075 | 4.97% |
Iron Triangle Partners LP | 130,000 | $32,012,500 | 4.68% |